Particularities of Clostridium Difficile Infection in Patients with Psychiatric Pathology

Liliana BAROIU¹, Lucreţia ANGHEL², Caterina DUMITRU³, Alina Viorica IANCU⁴, Miruna DRĂGĂNESCU⁵, Anamaria CIUBARA⁶

¹ Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, lilibaroiu@yahoo.com
² Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, anghel_lucrtia@yahoo.com
³ Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, dumitrucati@yahoo.com
⁴ Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, iancualina_2003@yahoo.com
⁵ Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, draganescumiruna@yahoo.com
⁶ Clinical Department, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 47 Domneasca St., 800008, Galati, Romania, anamburea@yahoo.com

Abstract: Clostridium difficile infection (CDI) is a new pathology, but increasingly common in the elderly patient, with multiple comorbidities that often alter his quality of life and aggravate his vital prognosis. Material and method: The study is a prospective, observational, controlled active study, performed on 706 patients admitted to the Hospital ”St. Parascheva Galați Infectious Diseases Clinical Hospital ” between 1.01.2017 ÷ 31.12.2018 with the diagnosis of CDI, of which 69 patients were associated with psychiatric disorders (PD). Results: The demographic, clinical and paraclinical characters that differentiated the group with CDI and PD from the group with CDI and various comorbidities, statistically significant, were: female sex, predominant in the group with PD, older age in the group with PD, Charlson score with values higher in the PD group, Atlas score with higher values in the PD group, the number of deaths that occurred in the first 30 days after the CDI episode, as well as the number of deaths that occurred in the first 6 months after the CDI, higher in the group with CDI and PD compared to the group with CDI and various comorbidities.

Keywords: Clostridium difficile; comorbidities; dementia; prognosis.

How to cite: Baroiu, L., Anghel, L., Dumitru, C., Iancu, A.V. Drăgănescu, M., & Ciubara, A. (2020). Particularities of Clostridium Difficile Infection in Patients with Psychiatric Pathology. BRAIN. Broad Research in Artificial Intelligence and Neuroscience, 11(1Sup2), 01-11. https://doi.org/10.18662/brain/11.1Sup2/32
Introduction

Clostridium difficile Infection (CDI) is an important public health problem in Romania. In 2018, a number of 10241 confirmed cases entered in the CDI surveillance system, with 2% more cases than 2017 (10080). The elderly were mainly affected, the median age of confirmed cases was 68 years (0-101 years), 51% being female.

Risk factors for triggering the episode of CDI are: antibiotic therapy, age over 65 years, contact with medical care units, cancer chemotherapy (Bilgrami et al., 1999; Gorschulator et al., 2001), gastrointestinal surgery (Sartelli et al., 2019; Thibault, Miller & Gaese, 1991), feeding on the nasogastric tube, upper or lower digestive endoscopy (Bliss et al., 1998), patient's comorbidities (chronic or disabling diseases accompanied by immunosuppression).

Risk factors for mortality from CDI are considered: age, comorbidities, hypoalbuminemia, leukocytosis, acute renal failure and ribotype 027 infection (Abou Chakra et al., 2014).

Psychiatric pathology is not usually accompanied by CDI, but there are studies that have observed high rates of CDI in patients with dementia in long-term care facilities (LTCF). In the United States, the rate of CDI in LTCF is 1.85 / 100 LTCF admissions with a 3-month mortality rate higher than those without CDI (Ziakas et al., 2016). The risk of CDI among LTCF residents is seven times higher compared to individuals in the community (Karanika et al, 2017). This increased risk is due to multiple risk factors for CDI in this patient population, including age, frequent antimicrobial exposure, multiple comorbidities, and recurrent hospitalizations (Karanika et al., 2017; Ziakas et al., 2015; Ziakas et al, 2016).

These conditions of patients are associated with changes in the structure of the microbiome (Lewis & Pamer, 2017). The study of the microbiome in patients with advanced dementia, living in a long-term care unit, showed a reduced diversity of commensal species. Thus, the diversity of the microbiome, as measured by the Shannon index, was substantially reduced in these patients, with a value of 3.2, than the reported values of 4.5 among the general population (Antharam et al., 2013).

Reconstruction of the microbiome could reduce the risk of CDI onset and recurrence. The identification of disturbances of the microbiome could identify patients with high risk of CDI and allow the formulation of preventive and therapeutic strategies targeted for CDI (Araos et al., 2018,
Particularities of Clostridium Difficile Infection in Patients with Psychiatric …
Liliana BAROIU, et al.

Manges et al., 2010, May, 2018; Theriot & Young, 2015; Vincent & Manges, 2015; Vincent et al., 2013).

Also, patients colonized with Clostridium difficile toxigenic strains have an increased risk of CDI. The structure of the microbiome in patients with dementia from long-term care facilities, who are colonized with Clostridium difficile toxigenic strains differs from non-colonized patients by the predominance of: Akkermansia spp., Dermabacter spp., Romboutsia spp., Meiothermus spp., Peptoclostridium spp., and Ruminococcaceae UGC 009 (Araos et al., 2018). Also, colonization with C. difficile is associated with a six-fold increased risk of CDI (Zacharioudakis et al., 2015). Specific microbiome disturbance indices may be able to identify subjects at high risk of C. difficile colonization and may help formulate targeted prevention and therapeutic strategies within LTCF (Anghel et al., 2019; Baroiu et al., 2018; Baroiu et al. 2019; Berbinschi et al., 2014; Zacharioudakis et al., 2015).

Other clinical studies have observed a higher incidence of CDI in elderly Americans with depression than in those without depression (282.9 / 100,000 person-years (95% CI 226.3 - 339.5) compared to 197.1 / 100,000 person-years (95% CI 168.0 - 226.1)). In this study, the rate of CDI was 36%, higher in patients with major depression (95% CI 1.06 ÷ 1.74). The conclusion of the study was that adults with depression who use antidepressant medication have a higher risk of CDI than the general population, with the highest risk being present in elderly widowed adults and those living alone (Rogers et al., 2013).

A United States study of 362 patients with CDI found that delirium, Charlson score, total leukocyte count, serum urea, intensive care hospitalization were predictive factors for 30-day mortality from the episode of CDI. Of these factors - patients who were admitted from a long-term care facility, diagnosed in the intensive care unit, and who developed delirium were at highest risk for dying within 30 days of CDI diagnosis (Archbald-Pannone et al., 2016).

This paper aims to identify the specific features of CDI in patients with psychiatric disorders from an epidemiological, clinical and therapeutic point of view.

Methodology

A prospective, observational, actively controlled study was performed on 706 patients admitted to the “St. Parascheva Clinic Hospital of Infectious Diseases Galati” between 1.01.2017 ÷ 31.12.2018 with the diagnosis of Clostridium difficile Infection. 69 of them had psychiatric
comorbidities. Criteria for inclusion in the study were: adults with unformed stools, over 3 in the last 24 hours, with a consistency of 6-7 on the Bristol scale and toxins of Clostridium difficile A or B or A and B positive; patients who have written informed consent for participation in the study, staff in full knowledge.

Exclusion criteria from the study were: unconscious patients or inability to sign informed consent; patients who refused to participate in the study; pregnant or breastfeeding women; patients under 18 years; patients who had extreme values ("outliers") in the usual laboratory tests (leukocytes, hemoglobin, serum albumin, ionogram, serum creatinine).

Patients were monitored during the hospitalization period and at one month, 2 months and 6 months after discharge, they were evaluated by telephone or in hospital.

For statistical analysis we used Med Calc program, version 15.8. Statistical analysis of the demographic data was performed on the group of patients with CDI and psychic diseases (group A) compared to the one with CDI and various comorbidities (group B). The presentation is in Mean, S.D. (standard deviation), minimum and maximum value for continuous variables and in absolute frequency for categorical variables, the test used in the inferential analysis being specified for each variable.

**Results**

The diagnoses of patients with psychiatric disorders were: dementia-75.36% of cases, depressive disorder-8.69%, anxio depressive disorder-4.34%, schizophrenia-4.34%, anxiety disorder-2.89%, severe mental retardation-1.44%, organic affective disorder-1.44%, persistent delirium-1.44%, Fig.1.

![Fig 1. Profile of psychiatric pathology](image_url)
The origin of the cases in the group with patients with CDI and various comorbidities was: 553 (78.32%) patients with infection associated with healthcare, and 153 (21.67%) patients with infection with indefinite and community source, and in the group of patients with CDI and psychiatric disorders (PD) was: 61 (88.40%) patients with healthcare associated infection, and 8 (11.59%) patients with indefinite and community source infection. The percentage of nosocomial infections was higher in the PD group with 10.08% (95% CI -0.33% -17.29%, p = 0.0697) without being statistically significant. The characteristics of the group with CDI and PD and the group with CDI and various comorbidities and their statistical correlation are presented in Table 1 and 2.

**Table 1. Numeric correlations of the characteristics of the group with CDI and psychiatric disorders versus CDI and various comorbidities**

|                          | CDI+PD+ (N=69) | CDI+ (N=706) | T-t | 95% CI         |
|--------------------------|----------------|--------------|-----|---------------|
|                          | Av. | SDev | Max; Min | Av. | SDev | Max; Min | p   |               |
| Age (years old)          | 75.71 | 13.29 | 91;21     | 66.23 | 15.37 | 95;19     | <0.0001 | -13.24; -5.71 |
| Hospitalization length (days) | 8.88 | 4.68 | 28; 1     | 8.09 | 3.57 | 28; 1     | 0.0853 | -1.71; 0.11  |
| Treatment duration (days) | 9.76 | 3.25 | 21; 1     | 10.19 | 3.27 | 35; 1     | 0.2972 | -0.37; 1.23  |

Legend: Av=Average; SDev=Standard Deviation; Max=Maximum Value; Min= Minimum value; T-t= Student Test (t) for differences between means; CI= conficence interval

**Table 2. Statistic analysis of the characteristics of categorical variables of the patients with CDI and psychiatric disorders versus CDI and various comorbidities**

|                          | CDI+PD+ N=69 | CDI+ N=706 | OR 95%CI | X2 Test | p   |
|--------------------------|--------------|------------|----------|---------|-----|
|                          | n          | %          | n        | %          |     |
| Sex                      |             |            |          |            |     |
| Female                   | 41          | 59.42      | 314      | 44.47     | 1.89-27.19 | 0.0243 |
| Male                     | 28          | 40.57      | 392      | 55.52     |               |        |
| Living Area              |             |            |          |            |     |
| Urban                    | 52          | 75.36      | 477      | 67.56     | -4.54-18.03 | 0.2329 |
| Rural                    | 17          | 24.63      | 229      | 32.43     |               |        |
| Charlson Score           |             |            |          |            |     |
| 0-3                      | 8           | 11.59      | 301      | 4.39      | 0.50-17.27   | <0.0001 |
| 4-6                      | 30          | 43.47      | 270      | 38.24     | -7.23-18.21  | 0.0202  |
| 7-14                     | 31          | 59.42      | 135      | 19.12     | -0.4704     |        |
|                          | Yes | No      | Yes | No      | 27.42-52.30 |            |         |
|--------------------------|-----|---------|-----|---------|-------------|-----------|---------|
| Antibiotics before CDI   | Yes | 50      | 19  | 72.46   | 27.53       | 65.86     | 34.13   |
|                          | No  | 19      | 50  | 72.46   | 27.53       | -5.97     | 17.30   |
| PPI before CDI onset     | Yes | 24      | 45  | 34.78   | 65.21       | 27.90     | 72.09   |
|                          | No  | 45      | 24  | 34.78   | 65.21       | -4.72     | 19.73   |
| Endoscopy before CDI     | Yes | 2       | 67  | 2.89    | 97.10       | 4.10      | 95.89   |
|                          | No  | 67      | 2   | 2.89    | 97.10       | -6.09     | 4.28    |
| Abdominal Surgery        | Yes | 3       | 66  | 4.34    | 95.65       | 9.77      | 90.22   |
|                          | No  | 66      | 3   | 4.34    | 95.65       | -2.67     | 9.64    |
| ATLAS Score              | 0-3 | 37      | 50  | 53.62   | 46.37       | 83.00     | 16.92   |
|                          | 4-9 | 32      | 46  | 53.62   | 46.37       | 16.99     | 42.08   |
| Recurrence               | Yes | 13      | 56  | 18.84   | 81.15       | 12.4      | 82.43   |
|                          | No  | 56      | 13  | 18.84   | 81.15       | 7.65      | 12.82   |
| Deaths 0-30 days         | Yes | 19      | 50  | 27.53   | 72.46       | 10.48     | 89.51   |
|                          | No  | 50      | 19  | 27.53   | 72.46       | 6.67      | 29.32   |
| Deaths 0-6 months        | Yes | 63      | 6   | 91.30   | 8.69        | 18.13     | 81.86   |
|                          | No  | 6       | 63  | 91.30   | 8.69        | 63.40     | 79.27   |

**Demographic characters.** In the group with CDI and PD, the female sex predominated as opposed to the one with CDI and various comorbidities in which the male predominated (statistically significant differences). In both lots the urban environment of origin predominates.

**Analysis of risk factors.** Patients with PD are older when they develop the episode of CDI than those with other pathologies associated. The mean age of the group with PD falls in the second degree of severity of the Atlas score (70-79 years) and the average age of the group with CDI and various comorbidities fall into the first degree of severity of the Atlas score (60-70 years), the difference of these means being statistically significant. The median age of both groups (79 years, group A, 68 years, group B) is in the risk zone for CDI (over 65 years).

The consumption of antibiotics and the chronic consumption of proton pump inhibitors (PPIs), before the onset of CDI, had not statistically significant differences between the two groups. Abdominal surgery and diagnostic or therapeutic endoscopies during the last 8 weeks before the onset of CDI, had similar proportion in the two groups.
The comorbidities of patients with CDI, as measured by the Charlson score, revealed statistically significant differences in the profile with various comorbidities and with PD. The patients with PD accumulated a proportion of value for Charlson Score 7-14 significantly higher than those with CDI and various comorbidities.

*Analysis of the severity of the episode and the prognosis of CDI.* The severity of the CDI episode, as quantified by the ATLAS Score, reveals statistically significant differences on the episodes of high severity disease, that is, the patients with PD experienced significantly more episodes of CDI with Atlas severity index 4-9 more than those with CDI and various comorbidities.

The length of hospitalization and the number of days of specific antibiotic treatment were comparable in the two study groups.

The number of recurrences, defined as the recurrence of symptoms with more than 3 stools, consistency 6-7 on the Bristol Scale, in the last 24 hours and toxins A and / or B positive for CD, in the first 8 weeks after the clinical resolution of the studied episode by CDI, was comparable in the two study groups.

The number of deaths occurring during the first 30 days after the CDI episode, as well as the number of deaths occurring during the first 6 months after the CDI, were statistically significantly higher in the group with CDI and PD compared with the group with CDI and various comorbidities, in direct correlation with the fact that these patients were older and with a profile of comorbidities, with a higher risk of death, and they experienced episodes of disease with higher severity (quantified by the Atlas score) (Perju-Dumbravă et al., 2013).

**Discussions**

The study of patients with CDI and PD compared with those with various comorbidities identifies risk factors with significant importance in this group, such as older age and more complex profile of comorbidities, with higher risk of death (as measured by the Charlson score). Disorders of diversity and quantity of the microbiome described in literature in patients with dementia, who predominate in our group with PD, could also explain the high severity of the episode of CDI and the severe prognosis of CDI in these patients.

The higher severity of CDI episodes in PD patients, the older age, the complex comorbidity profile and the dysbiosis encountered in these patients had a statistic significant impact on the prognostic of these patients,
quantified by the death rate at 1 month and 6 months from the CDI episode (Perju-Dumbravă et al., 2010).

**Conclusion**

Prevention measures for CDI should be carefully and rigorously implemented in patients with PD, especially in patients living in long-term care centers but also in those living at home because their risk profile predisposes to the onset of CDI and to the development of episodes of severe disease with reserved prognosis. The correction of microflora imbalances in the colon in psychiatric patients should be considered when designing their chronic treatment schemes, prophylactic and curative therapies with PPIs and antibiotics should be well reviewed and performed only when are strictly necessary. Further studies will evaluate the usefulness of screening healthy Clostridium difficile carriers when hospitalized in a psychiatric ward or in a long-term care unit.

**References**

Abou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014). Risk factors for recurrence, complications and mortality in CDI: a systematic review. *PLoS One, 9*, e98400. [https://doi.org/10.1371/journal.pone.0098400](https://doi.org/10.1371/journal.pone.0098400)

Anghel, L., Baroiu, L., Beznea, A., Topor, G., & Grigore, C. (2019). The Therapeutic Relevance of Vitamin E. *Revista de Chimie, 70*(10), 3711–3713. [https://doi.org/10.37358/RC.19.10.7630](https://doi.org/10.37358/RC.19.10.7630)

Antharam, V. C., Li, E. C., Ishmael, A., Sharma, A., M., Volker, Rand, K. H., & Wang, G. P. (2013). Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. *Journal of Clinical Microbiology, 51*(9), 2884–2892. [https://doi.org/10.1128/JCM.00845-13](https://doi.org/10.1128/JCM.00845-13)

Araos, R., Andreatos, N., Ugalde, J., Mitchell, S., Mylonakis, E., & D'agata, E. M. C. (2018). Fecal Microbiome Among Nursing Home Residents With Advanced Dementia And Clostridium Difficile. *Digestive Diseases and Sciences, 63*(6), 1525 – 1531. [https://doi.org/10.1007/s10620-018-5030-7](https://doi.org/10.1007/s10620-018-5030-7)

Archbald-Pannone, L. R., Memmury, T. L., Guerrant, R. L., & Warren, C. A. (2016). Delirium And Other Clinical Factors With Clostridium Difficile Infection That Predict Mortality In Hospitalized Patients. *American Journal of Infection Control, 43*(7), 690 – 693. [https://doi.org/10.1016/j.ajic.2015.03.017](https://doi.org/10.1016/j.ajic.2015.03.017)

Baroiu, L., Beznea, A., Pleșea Condratovici, C., Onisor, C., Grigore, C. A., Topor, G., & Rugina, S. (2019). Comparative Effectiveness of Vancomycin and Metronidazole for the Initial Episode of Nonsevere Clostridium Difficile
Particularities of Clostridium Difficile Infection in Patients with Psychiatric …
Liliana BAROIU, et al.

Infection. *Revista de Chimie*, 70(10), 3741 – 3745.  
https://doi.org/10.37358/RC.19.10.7637

Baroiu, N., Baroiu, L., Teodor, V. G., & Ciocan, T. L. (2018). Gaphical method for profiling the side mill which generate helical flute of tungsten carbide dental cross cut bur. *Romanian Journal of Materials* 48(1), 131–139.

Berbinschi, S., Baroiu, N., Teodor, V., & Oancea, N. (2014). Profiling method of side mill for threading screw for dental implants. *Advanced Materials Research*, 837, 22–27. https://doi.org/10.4028/www.scientific.net/AMR.837.22

Bilgrami, S. Feingold, J. M., Dorsky, D., Edwards, R. L., Bona, R. D., Khan, A. M., Rodriguez-Pinero, F., Clive, J., & Tutschka, P. J. (1999). Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 23, 1039 – 1042.  
https://doi.org/10.1038/sj.bmt.1701773

Bliss, D. Z., Johnson, S., Savik, K., Clabots, C. R., Willard, K., & Gerding, D. N. (1998). Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. *Annals of Internal Medicine*, 129, 1012–1019.  
https://doi.org/10.7326/0003-4819-129-12-199812150-00004

Gorschluter, M., Glasmacher, A., Hahn, C., Schakowski, F., Ziske, C., Molitor, E., Marklein, G., Sauerbruch, T., & Schmidt-Wolf, I. G. H. (2001). Clostridium difficile infection in patients with neutropenia. *Clinical Infectious Diseases*, 33(6), 786 – 791.  
https://doi.org/10.1086/322616

Karanika, S., Grigoras, C., Flokas, M. E., Alevizakos, M., Kinamon, T., Kojic, E. M., & Mylonakis, E. (2017). The attributable burden of Clostridium difficile infection to long-term care facilities stay: a Clinical Study. *Journal of the American Geriatrics Society*, 65, 1733 – 1740.  
https://doi.org/10.1111/jgs.14863

Lewis, B. B., & Pamer, E. G. (2017). Microbiota-based therapies for Clostridium difficile and antibiotic-resistant enteric infections. *Annual Review of Microbiology*, 71, 157 – 178.  
https://doi.org/10.1146/annurev-micro-090816-093549

Manges, A.R., Labbe, A., Loo, V.G., Behr, M. A., Masson, L., Tellis, P. A., & Brousseau, R. (2010). Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. *The Journal of Infectious Diseases*, 202(12), 1877–1884.  
https://doi.org/10.1086/657319

May, B. (2018, April 11). Microbiome Composition Offers Insight Into Clostridium Difficile Risk Among Dementia Patients. *HCP Live*.  
https://www.mdmag.com/medical-news/microbiome-composition-offers-insight-into-clostridium-difficile-risk-among-dementia-patients
Perju-Dumbravă, D., Anitan, S., Siserman, C., Fulga, I., & Opincaru, I. (2010). Virtopsy – An Alternative To Conventional Autopsy. *Romanian Journal Of Legal Medicine, 18*(1), 75-78.

Perju-Dumbravă, D., Fulga, I., Chirobă, O., & Bulgaru-Ilieșcu, D. (2013). Ethical And Diagnostic Difficulties Of The Cohabitation Tests In The Forensic Expertise. *Revista Romana de Biotehnica, 11*(4), 132-137.

Rogers, M., Greene, T., Young, V. B., Saint, S., Langa, K. M., Kao, J. Y., & Aronoff, D. M. (2013). Depression, antidepressant medications, and risk of Clostridium difficile infection. *BMC Medicine 11*(1), 121. https://doi.org/10.1186/1741-7015-11-121.

Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., Ben-Ishay, O., Biffí, W. L., Brecher, S. M., Camacho-Ortiz, A., Cánizos, M. A., Shirley Chan, S., Cherry-Bukowiec, J. R., Clanton, J., Coccolini, F., Cocuz, M. E., Coimbra, R., Cortese, F., Cui, Y., Czepiel, J., Demetrashvili, Z., Di Carlo, I., Saverio, S. D., Dumitru, I. M., Eckmann, C., Eiland, E. H., Forrester, J. D., Fraga, G. P., Frossard, J. L., Fry, D. E., Galeiras, R., Ghanam, W., Gomes, C. A., Griffiths, E. A., Guirao, X., Ahmed, M. H., Herzog, T., Il Kim, J., Iqbal, Isik, A., Itani, K. M. F., Labricciosa, F. M., Lee, Y. Y., Juang, P., Karamarkovic, A., Kim, P. K., Kluger, Y., Leppaniemi, A., Lohsiriwat, V., Machain, G. M., Marwah, S., Mazuski, J. E., Metan, G., Moore, E. E., Moore, F. A., Ordoñez, C. A., Pagani, L., Petrosillo, N., Portela, F., Rasa, K. R., Rems, M. R., Sakakushev, B. E., Segovia-Lohse, H., Sganga, G., Shelat, V. G., Spigaglia, P., Tattevin, P., Tranà, C., Urbánek, L., Ulrych, J., Viale, P., Baiocchi, G. L., & Catena, F. (2019). 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. *World Journal of Emergency Surgery, 14*(1), 8. https://doi.org/10.1186/s13017-019-0228-3.

Thibault, A., Miller, M. A., & Gaese, C. (1991). Risk factors for the development of *Clostridium difficile*-associated diarrhea during a hospital outbreak. *Infection Control and Hospital Epidemiology, 12*(6), 345–388. https://doi.org/10.2307/30145209.

Theriot, C. M., & Young, V. B. (2015). Interactions between the gastrointestinal microbiome and *Clostridium difficile*. *Annual Review of Microbiology, 69*, 445–461. https://doi.org/10.1146/annurev-micro-091014-104115.

Thibault, A., Miller, M. A., & Gaese, C. (1991). Risk factors for the development of *Clostridium difficile*-associated diarrhea during a hospital outbreak. *Infection Control and Hospital Epidemiology, 12*(6), 345–388. https://doi.org/10.2307/30145209.

Vincent, C., & Manges, A.R. (2015). Antimicrobial use, human gut microbiota and *Clostridium difficile* colonization and infection. *Antibiotics (Basel) 4*(3), 230–253. https://doi.org/10.3390/antibiotics4030230.

Vincent, C., Stephens, DA., Loo, VG., Edens, T. J., Behr, M. A., Dewar, K., & Manges, A. R. (2013). Reductions in intestinal Clostridiales precede the
development of nosocomial Clostridium difficile infection. *Microbiome*. 1, 18. https://doi.org/10.1186/2049-2618-1-18

Zacharioudakis, I.M., Zervou, F.N., Pliakos, E.E., Ziakas, P. D., & Mylonakis, E. (2015). Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. *American Journal of Gastroenterology*, 110(3), 381–390. https://doi.org/10.1038/ajg.2015.22

Ziakas, P. D., Joyce, N., Zacharioudakis, I. M., Zervou, F. N., Besdine, R. W., Mor, V., & Mylonakis, E. (2016). Prevalence and impact of Clostridium difficile infection in elderly residents of long-term care facilities, 2011: a nationwide study. *Medicine (Baltimore)*, 95(31), e4187. https://doi.org/10.1097/MD.0000000000004187

Ziakas, P. D., Zacharioudakis, I. M., Zervou, F. N., Grigoras, C., Pliakos, E. E., & Mylonakis, E. (2015). Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factors. *PLoS ONE*, 10(2), e0117195. https://doi.org/10.1371/journal.pone.0117195